Elucidating the exact pharmacological system of action (MOA) of naturally transpiring compounds is usually difficult. While Tarselli et al. (60) produced the initial de novo artificial pathway to conolidine and showcased that this naturally developing compound proficiently suppresses responses to the two chemically induced and inflammation-derived